BMJ22h
OP0040 DOSE DEPENDENT MODULATION OF PROTEOMIC SIGNATURES BY IANALUMAB IN PATIENTS WITH SJÖGREN’S DISEASE
1 Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands 2 Department of Rheumatology and Clinical Immunology, ...
BMJ1d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ1d
Huntingtin-interacting protein 1 (HIP1) regulates arthritis severity and synovial fibroblast invasiveness by altering PDGFR and Rac1 signalling
Objectives While new treatments for rheumatoid arthritis (RA) have markedly improved disease control by targeting immune/inflammatory pathways, current treatments rarely induce remission, underscoring ...
BMJ2d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...
BMJ2d
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
BMJ2d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ3d
Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis
Department of Rheumatology, Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, University of Tel Aviv, Israel Correspondence to: Dr O Elkayam, Department of Rheumatology, Tel ...
BMJ4d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ5d
Genetics of rheumatoid arthritis: 2018 status
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
BMJ10d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ15d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ23d
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
Objectives Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) share many clinical manifestations and serological features. The aim of this study was to ...